Introduction
Surgical bleeding is a common occurrence and varies widely in presentation and consequences across surgery types. [1] [2] [3] [4] [5] Surgical bleeding can range from mild or moderate in intensity to uncontrolled or traumatic. Some bleeding scenarios may be straightforward to manage; however, bleeding can also become more problematic, depending on several factors, including bleeding intensity, anatomic location, visibility and accessibility of bleeding source, and coagulation status. 6 Problematic types of bleeding scenarios may be referred to in the literature using several common bleeding terms, including severe, major, uncontrollable, or excessive. For example, diffuse bleeding from broad surface areas in coagulopathic patients may be difficult submit your manuscript | www.dovepress.com
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Corral et al to control, which can lead to complications, such as transfusions. 1, 6, 7 Uncontrollable bleeding is also often encountered in fragile or friable tissues, such as in liver resections. 1, 4, 5 Problematic surgical bleeding is frequently associated with important clinical and cost burden. [8] [9] [10] [11] [12] Literature capturing "excessive" or "uncontrolled" surgical bleeding reported mortality rates as high as 20%, with a fivefold increase in death if coagulopathy is present. 2, 7 Problematic bleeding can also be associated with substantial hospital resource use due to increased risk of transfusion, higher risk of complications, longer procedure times, and reoperation. 2, 4, 9, [13] [14] [15] [16] A large, US premier database study demonstrated that all-cause costs were significantly higher in patients with uncontrolled ($24,203 to $61,323) compared with controlled ($14,420 to $45,593) bleeding (P<0.001). 17 In some bleeding situations, conventional surgical methods (eg, sutures or clips) to control bleeding may be impractical or ineffective. 16, 18, 19 As a result, these situations often require the use of adjunctive agents, such as topical absorbable hemostats or fibrin sealants. 1, 20 Although there are several products available, their efficacy in controlling bleeding can be limited, with uncontrolled bleeding remaining a prevalent problem. 17, 21 Recent data have highlighted this issue by demonstrating that 32% to 68% of surgical cases involve major bleeding, despite the use of current hemostatic agents. 17 The Evarrest ® Fibrin Sealant Patch (Ethicon U.S., LLC, Somerville, NJ, USA) is an advanced topical absorbable hemostat composed of well characterized and commonly used materials (polyglactin [PG910], oxidized regenerated cellulose [ORC] , human thrombin, and human fibrinogen). There is a growing body of evidence that demonstrates the safety and effectiveness of this fibrin sealant patch in a variety of tissue types and across a spectrum of bleeding intensities. [22] [23] [24] [25] In mild-to-moderate soft tissue surgical bleeding, 98.3% of patients with the fibrin sealant patch and 53.3% with Surgicel ® Original (Ethicon U.S., LLC, Somerville, NJ, USA) achieved hemostasis at 4 minutes (P<0.0001). 22 This treatment differential was magnified with increasing bleeding intensity. Another trial in severe soft tissue bleeding showed that the fibrin sealant patch was also safe and effective compared with standard of care (SoC) (ie, gauze ± ORC). 23 In the two hepatic tissue surgical bleeding trials, 82.5% and 95.7% of patients with the fibrin sealant patch compared to 29.5% and 42.9% of patients with SoC achieved hemostasis at 4 minutes (P<0.001). 24, 25 In these hepatic bleeding trials, SoC was sometimes an ORC and sometimes manual compression with or without another type of hemostat. Several types of resource (eg, transfusions, retreatment) have been reported to be numerically lower with the fibrin sealant patch in the trials. [22] [23] [24] [25] In light of recent health care reform measures, it is essential for hospitals to optimize resource use in hospitals. The clinical trial data for the fibrin sealant patch in soft tissue and hepatic surgical bleeding capture important hospital resource outcomes. The objective of our study was to therefore perform a modeled hospital cost analysis for the fibrin sealant patch compared with SoC across a range of hepatic and soft tissue bleeding scenarios.
Methods
A cost analysis model, developed using Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA, USA), quantified the 30-day per patient cost impact of the fibrin sealant patch compared with SoC from a hospital decision-maker perspective (eg, value analysis committees). The analysis incorporated aggregated resource use from four clinical trials of the fibrin sealant patch versus SoC in surgical bleeding, in which the SoC arm varied to some extent across trials. [22] [23] [24] [25] The soft tissue surgical bleeding trials primarily compared the fibrin sealant patch with ORC/Surgicel ® Original (88% 23 to 100% 22 ORC/Surgicel ® Original). The two hepatic surgical bleeding trials compared the fibrin sealant patch with a mix of ORC (ie, 34% to 69%) and conventional methods (or other hemostats). 24, 25 Table S1 provides the detailed breakdown of products used as the initial treatment in the SoC arm of the four clinical trials. The primary outcome in all trials was the proportion of patients achieving hemostasis at 4 minutes. Further, the definitions for resource data collection remained generally consistent across all four trials. Published US unit costs were assigned to resource outcomes, and the total costs of the fibrin sealant patch and SoC were quantified. The study population therefore reflects a broad range of patients across several surgical specialties (excluding transplant patients). Ethics approval was gathered for the clinical studies that informed this costing analysis. As the costing analysis in this study did not involve contacting patients or obtaining further data than what was already reported in the clinical study, ethics approval was not obtained for the current costing analysis.
Resource inputs from clinical trial
In the budget impact analysis, resource outcomes were based on data reported for the intention-to-treat populations and incorporated using mean values across treatment groups where applicable. The resource outcomes were collected from multinational trials, including the US, Europe, Australia, and New Zealand. [22] [23] [24] [25] For initial product cost, the actual amount and size of the fibrin sealant patch were quantified. Using individual patient level data, target bleeding site <52 cm 2 were 24, 25 Details of the SoC breakdown taken from the clinical study reports (ie, available to the public via correspondence with authors) can be found in Table S1 .
Mean trial-reported values were used in the budget impact analysis for operation time, transfusion risk prior to discharge, transfusion units, retreatment risk and related product use, length of postoperative stay, and ventilator hours. These outcomes were incorporated into the analysis regardless of statistical significance. For transfusion units, all products were included in the analysis (ie, packed red blood cells, whole blood, fresh frozen plasma, platelets, cryoprecipitate, albumin, autologous blood, and leuko-depleted blood). In the trials, if hemostasis was not achieved after 4 minutes, retreatment was defined as the need for additional intervention due to bleeding at the target bleeding site during an additional 6-minute observation period. Retreatment product utilization was quantified per patient based on actual product usage reported from the clinical trials (Table S2 ). The majority of outcomes had minimal amounts of missing data (ie, <5%) and therefore imputations were generally not conducted. Data were imputed in one case where the transfusion units were not recorded for two fibrin sealant patch patients and one SoC patient. In these cases, imputation was completed based on respective patient-reported blood loss.
Cost inputs
Aggregated resource outcomes reported in the trials were costed using published sources and inflated to 2015 US costs using the Consumer Price Index for US medical care. 26 Unit costs for all products used in the four trials are outlined in Tables S1 and S2. The initial hemostat application cost was based on the specific product size (if noted). List or published prices were applied. If product size was not noted in the clinical study report, the average unit cost across product sizes was applied. For the fibrin sealant patch, each 5.1×10.2 cm pad was assigned a unit cost of $1,300. 27 For SoC, acquisition cost was calculated for each trial based on use and unit costs. In cases where nonconsumable conventional methods were used, it was conservatively assumed that no cost be attributed as these options would have been available as part of routine hemostatic methods. With manual compression, an average of several unit prices was used for BloodSTOP hemostatic gauze to reflect the need for some gauze during this practice. 28 Other assumptions used in the analysis include the unit cost of collagen and gelatin, which were assumed to be the prices of TachoSil ® and Surgiflo ® (Ethicon U.S., LLC, Somerville, NJ, USA), respectively. The overall weighted SoC product acquisition costs are summarized in Table 1 .
The cost of operating room time was taken from a study that reported a fee of ~$62 per minute. 29 This cost was added to per minute reported salary for an operating room nurse ($0.61) 30 and anesthesiologist fee ($6.65) 31 to formulate a cost of $92.54 per 1 minute of surgery after inflation to 2015 dollars. The cost of hospital stay was informed by the Kaiser Family Foundation, with a cost of $2,186 per day. 32 This was multiplied by 59% to account for room and board only, resulting in a cost of $1,290 per day, which was used in the analysis. 33 Unit costs for various transfusion blood products were taken from published literature. [34] [35] [36] For each trial, a weighted average cost for each blood unit type was calculated for the treatment groups with 2015 average cost per unit ranging from $223 to $255. These values reflected blood acquisition costs only and did not include indirect costs. The hourly cost of ventilator use was reported as the daily cost of mechanical ventilation in intensive care and inflated to $96.66 per hour. 37 Table S2 captures unit costs and weighted average costs for retreatment according to treatment arms for the four clinical studies. No additional costs were conservatively assumed for nonconsumable conventional methods. The weighted average cost of retreatment for the overall trial population was calculated to range from $90.06 to $347.90 per patient across the four trials. Table 1 summarizes the resource use and unit cost input values used in the base case cost analysis. The surgical analysis included resources deemed more clinically related to the significant hemostatic benefit of the fibrin sealant patch compared with SoC. These resources included the initial application products, retreatment products, surgery time, and transfusion use. A hospital analysis was also conducted that included all key resource outcomes reported in the trials. Both surgical and hospital analyses were conducted by calculating total costs for each trial (ie, resource use multiplied by unit costs) and weighting the results of the four trials by the trial sample sizes to estimate the composite total costs across trials. The weighting factors can be found in Table 1 (footnote).
Base case analysis
Subgroup analysis (coagulopathic patients)
Exploratory subgroup analyses of both the surgical and hospital analyses were conducted to assess the economic impact in coagulopathic patients. Patients were determined to be potentially coagulopathic and included in the analyses if any coagulation test parameter was outside of the reference range reported by the National Library of Medicine. Inclusion ranges were: >13.5 seconds prothrombin time, >35 seconds activated partial thromboplastin time, >1.1 international normalized ratio, and <2 g/L fibrinogen. [38] [39] [40] Aggregated clinical resource and cost inputs specific for these subgroup analyses are described in Table 2 . The average initial fibrin sealant patch utilization was conservatively assumed to be the same as the base case analysis. Similar to the base case, results were calculated based on weighted average resource use reported from the four clinical trials.
Sensitivity analysis
Uncertainty around analysis inputs was evaluated in a series of sensitivity analyses for both the surgical and hospital analyses using the overall four-trial composite results as the base case. One-way sensitivity analyses, varying individual fibrin sealant patch and SoC inputs concurrently, were conducted on all cost and resource inputs. These inputs were varied by standard deviation if available, or by adjusting base case values by ±20%. In addition to these sensitivity analyses, alternative inputs were tested according to the following:
• Initial fibrin sealant patch units: For lower and upper range estimates, it was assumed that all patients receive one pad ($1,300) or all patients receive two pads ($2,600). 
Results
The cost analysis predicted that the fibrin sealant patch compared with SoC is a cost-saving strategy for hospitals when used in soft tissue and hepatic surgical bleeding (Figure 1A and B; Table 3 ). The fibrin sealant patch was predicted to result in cost savings of $54 and $2,846 per patient, for the surgical and hospital analyses, respectively. Costed resource utilization was lower with the fibrin sealant patch compared with SoC for the majority of resources collected across all four trials (Table 3) . When considering only the soft tissue bleeding trials, the surgical analysis estimated that resource savings with the fibrin sealant patch completely offset its acquisition cost and resulted in a cost savings of $909 per patient compared with SoC. For the two hepatic bleeding trials, the surgical analysis estimated that the fibrin sealant patch was associated with a marginal cost impact of $788 per patient compared with SoC. Hospital analyses predicted cost savings for both the soft tissue trials ($4,837 per patient) and the hepatic bleeding trials ($863 per patient) (data not shown).
For the potentially coagulopathic subpopulations of the four trials, this exploratory analysis estimated that the use of the fibrin sealant patch compared with SoC would result in even greater cost savings for hospitals (Table 3 ). In the surgical analysis, the net difference in resource use was $4,693, which completely offset the incremental product acquisition cost ($1,459), resulting in a total cost savings of $3,233 per patient 
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Corral et al ( Figure 1C ). When additional resources were included for the hospital analysis, results predicted an increased cost savings for hospitals, with the total cost savings for the fibrin sealant patch predicted to reach $9,287 per patient ( Figure 1D ).
The model results were relatively robust to a number of variations in input values and assumptions. Figure 2A (surgical analysis) presents a tornado diagram where the input values were varied using standard deviations or 
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Cost analysis of fibrin sealant patch by ±20%. For the surgical analysis, many of the results remained cost saving. In sensitivity scenarios where the fibrin sealant patch was not cost saving, nearly all results showed that its acquisition cost was at least partially offset with averted resource use. Results were particularly sensitive to the cost per minute of operating room time and the units of product used. Sensitivity analyses on the hospital analysis ( Figure 2B ) demonstrated that all results remained cost savings irrespective of the parameters varied. The amount of cost savings was particularly sensitive to variation around ventilator time, length of stay, and operating time.
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Corral et al Table 4 presents additional one-way sensitivity analyses using alternative input values, such as additional literature sources. Results showed that most of the surgical analyses, and all of the hospital analyses, remained cost saving for the fibrin sealant patch compared with SoC. Results appeared most sensitive to lowering operating room cost per minute, as well as increasing the amount of fibrin sealant patch pads used per patient. Results were fairly insensitive to using alternative transfusion endpoints, inclusion of transfusion complications, and changing transfusion costs.
Discussion
This hospital cost impact analysis predicted that the fibrin sealant patch may be cost saving for hospitals when compared to SoC in soft tissue and hepatic surgical bleeding patients. Surgical analyses including only a subset of resources collected from the trials (ie, operation time, retreatment, and transfusions) still revealed that the fibrin sealant patch was cost saving compared with SoC; however, the magnitude of the cost savings was less ($54 per patient) compared with hospital analyses ($2,846 per patient) that incorporated all resources reported in the trials.
The predicted cost savings with the fibrin sealant patch become most apparent in more problematic bleeds. Specifically, in an exploratory subgroup analysis, the predicted hospital cost savings with the fibrin sealant patch increased to $9,287 per patient when focusing on the coagulopathic patients from the four trials, as the differences in resource use became larger between treatment arms. These economic findings align with efficacy data from preclinical and clinical studies. Specifically, a preclinical study reporting on efficacy data in coagulopathic bleeding found that the fibrin sealant patch achieved hemostasis in all cases compared to only 16.7% with the comparator hemostat. 45 The quantity of blood lost in this preclinical study was also less with the fibrin sealant patch. Further, in the clinical trials, the differences in hemostatic efficacy at 4 minutes, for the fibrin sealant patch versus SoC, were observed to be larger for more severe bleeding intensities compared with less severe intensities. 22, 23 Further economic analysis in coagulopathic specific populations are needed to verify our findings.
These study results were robust to a number of sensitivity analyses incorporating alternative sources, variation around point estimates, and additional resource items. For the majority of scenarios, the fibrin sealant patch remained cost saving relative to SoC. Results expectedly appeared most sensitive to variations around operation time given the high cost associated with operating room assumed in the base case and the high variability around the point estimate.
There is a wide range of costs reported for operating time in the literature and therefore we have assessed the impact of these different options. Surprisingly, results did not vary with the inclusion of literature-reported transfusion complication risk. These results can be explained by the fact that we remained conservative in informing this analysis with very low reported risk of such complications (eg, 0.0071% of patients transfused experienced a transfusion-related acute lung injury). In the scenarios that predicted a higher cost impact, a very high cost of the fibrin sealant patch or a very low cost of operating room time was assumed.
These results are aligned with recent US health care reform measures, which encourage coordinated care, cost Transfusions occurring at any time during the study includes both until discharge and postdischarge up to 60 days. 
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Cost analysis of fibrin sealant patch awareness, and high-quality care. 46, 47 As cost containment within hospitals becomes increasingly important, health economic analyses can be valuable tools that aid decision makers in the evaluation of the relative clinical benefits and economic impact of adopting new health care technologies. For several regions, including the US, the fibrin sealant patch may not receive separate reimbursement apart from the procedure according to diagnosis-related group structures. In these circumstances, it is critical to illustrate how hospital resources and costs can be averted with new innovative products.
This analysis focused on monetary outcomes partially based on aggregate resource data in the trial and as such is considered a cost analysis rather than a cost-effectiveness evaluation. Quality of life or health utility data are currently not available from the fibrin sealant patch trials and have not been reported for surgical hemostatic products in the literature. Further, mortality was not a primary or secondary endpoint in the fibrin sealant patch trials, rather captured as an adverse event and shown to be reasonably similar between groups. Given these reasons, a cost per quality-adjusted life year gained was not considered as a metric in this evaluation. Disease-specific incremental cost-effectiveness ratios are sometimes used in the context of reporting health economic results but have limitations in that the results can be difficult to interpret in the context of recommended thresholds and relative to other therapeutic categories for decision making. In the context of hemostatic products, cost analyses without incremental cost-effectiveness ratios are the types of evaluations most commonly reported in the literature. 48, 49 Overall, a few studies from the literature have shown that hemostatic products, such as fibrin sealants, may be associated with reduced resource utilization (eg, transfusion and length of hospital stay) compared with SoC. [48] [49] [50] [51] [52] [53] For example, a meta-analysis reported that overall use of fibrin sealants compared with no sealant significantly reduced the rate of blood transfusion by 37%. Positive trends were shown for other clinical outcomes, including hospital length of stay, although the meta-analysis did not show a statistically significant benefit. 51 The results of the current study are aligned with these published studies demonstrating that several types of hospital resources can be averted with hemostat products. As the fibrin sealant patch displays unique product characteristics and features relative to several currently marketed hemostats, it is expected that the magnitude of the results will vary according to comparator, bleeding intensity, and surgery type. 54 Interestingly, ventilator time was observed to be nonsignificantly lower with the fibrin sealant patch compared with SoC across trials. Using these data, such resource use was incorporated into our hospital-specific cost analysis that predicted additional cost savings with the fibrin sealant patch. Pulmonary resections did comprise approximately a quarter of surgeries for both trials; however, they appeared well-balanced between treatment groups. A factor that may help to explain this observation with the fibrin sealant patch pertains to transfusions. Evidence suggests that blood transfusion is associated with increased ventilator use, such as with the occurrence of lung-related transfusion complications. 55, 56 In further support, several studies have also reported that blood conservation initiatives and techniques have been shown to significantly reduce ventilator use. 57, 58 Taken together, these studies suggest an intricate relationship between the various types of resources averted with blood conservation methods, including hemostats, such as the fibrin sealant patch.
There are some limitations with this study. First, the clinical trials were not powered for resource outcomes as they were not primary endpoints. [22] [23] [24] [25] This may explain the lack of statistically significant reductions in resource outcomes with the fibrin sealant patch. Nevertheless, nonsignificant reductions in resource use were consistently observed with the fibrin sealant patch versus SoC across the range of outcomes, which was expected given the highly statistically significant benefits observed in hemostatic efficacy. These data suggest that an adequately powered study with resource outcomes as primary endpoints may achieve positive results. Health economic guidelines do recognize the issue that trials are often underpowered for detecting economic outcome differences. 59 A second limitation was that the SoC arm analyzed in two of the trials was primarily composed of Surgicel ® Original, which may not always reflect SoC in the real world. In reality, surgeons may be using other products that may be priced higher than Surgicel ® Original with currently unknown efficacy relative to the fibrin sealant patch. Use of these other products was partially reflected in retreatment product use within the trials; however, ongoing clinical trials are being conducted to assess head-to-head performance of the fibrin sealant patch versus other costly agents (eg, TachoSil ® ). 60 Third, adverse events were not explicitly included in the analysis as it was assumed that resource use outcomes reported in the trial primarily captured adverse event-related hospital consequences. There were also no trends observed in the adverse event data to suggest they would contribute substantially to the overall results of the analysis. Fourth, the clinical trials were multinational, reflecting resource use in the context of several different health care systems (ie, US, Europe, Australia, and New Zealand). Caution may therefore be needed in interpreting baseline resource use. Finally, the submit your manuscript | www.dovepress.com
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Corral et al analysis focused on the use of the fibrin sealant patch and comparators in the context of the target bleeding site and did not include implications of bleeding at sites other than the target site. Future, real-world studies may be helpful in addressing this issue.
In conclusion, this modeled analysis predicted that the fibrin sealant patch may result in important hospital cost savings in problematic soft tissue and hepatic bleeding. Further studies comparing the fibrin sealant patch use to that of other comparator hemostats and within larger study populations, particularly coagulopathic bleeding, are required to confirm these findings.
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Corral et al Notes: All costs are reported in US dollars and inflated to 2015 dollars using the Consumer Price Index. 9 Product sizes were not recorded in the clinical trial; as such, the cost of ORC, advanced ORC, and fibrin sealant were based on the average of all sizes available and Surgiflo ® cost includes thrombin. **Clinical study reports available to the public via correspondence with authors. Abbreviations: ORC, oxidized regenerated cellulose; SoC, standard of care. Notes: All costs are reported in US dollars and inflated to 2015 dollars using the Consumer Price Index. 9 Product sizes were not recorded in the clinical trial; as such, the cost of ORC, advanced ORC, and fibrin sealant were based on the average of all sizes available and Surgiflo ® cost includes thrombin. **Clinical study reports available to the public via correspondence with authors. Abbreviations: ORC, oxidized regenerated cellulose; SoC, standard of care. 
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